drugset / Trial / NCT01128296

Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

NCT01128296

NaSingle-groupOpen-labelTreatment

Summary

The primary goal of the research study is to determine whether treating pancreatic cancer patients with hydroxychloroquine in combination with gemcitabine before surgery is safe. The secondary goal is to determine if this new treatment regimen can effectively treat pancreatic cancer. This study will test the safety and efficacy of this combination in two parts, or phases.

Timeline

Start
2010-10
Primary completion
2013-04
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1500 mg/m2 Intravenous
Subject Hydroxychloroquine Small molecule 200 mg Oral
Subject Hydroxychloroquine Small molecule 400 mg Oral
Subject Hydroxychloroquine Small molecule 600 mg Oral
Subject Hydroxychloroquine Small molecule 800 mg Oral
Subject Hydroxychloroquine Small molecule 1000 mg Oral
Subject Hydroxychloroquine Small molecule 1200 mg Oral